Sphingosine-1-receptor modulators drugs[edit]
Drugs | Indication | Receptor selectivity | Status |
Fingolimod[2] | Multiple sclerosis (MS) | S1P1, S1P3, S1P4 and S1P5 | FDA approved 2010, EMA approved 2011 |
Ozanimod[2] | Multiple sclerosis (MS) and ulcerative colitits (UC) | S1P1 and S1P5 | FDA approved 2020 |
Siponimod[2] | Multiple sclerosis (MS) | S1P1 and S1P5 | FDA Approved 2019, EMA approved 2020 |
Ponesimod[2] | Multiple sclerosis (MS), psoriasis and graft vs. host disease | S1P1 | In Phase III clinical trials and Phase II trials. (*) |
Leave a comment: